# A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People

> **NCT01123915** · PHASE1 · TERMINATED · sponsor: **Medicines Development for Global Health** · enrollment: 22 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Opal-HIV-Gag(c) Low Dose
- **BIOLOGICAL:** Opal-HIV-Gag(c) Medium dose
- **BIOLOGICAL:** Opal-HIV-Gag(c) High dose
- **OTHER:** Dimethyl Sulfoxide

## Key facts

- **NCT ID:** NCT01123915
- **Lead sponsor:** Medicines Development for Global Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123915, "A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01123915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*